Top 5 Most Read Cholangiocarcinoma Articles in 2022

5. FDA Grants Accelerated Approval to Futibatinib for Locally Advanced, Metastatic Cholangiocarcinoma

Futibatinib (Lytgobi, Taiho Oncology, Inc) is indicated for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring FGFR2 gene fusions or other rearrangements. Read More.

4. Triplet Regimen With Durvalumab May Increase Overall Survival of Patients with Fatal Intrahepatic Cholangiocarcinoma

Promising data suggest triplet regimens may more effectively treat patients with unresected and metastatic intrahepatic cholangiocarcinoma. Read More.

3. C-reactive Protein Score May Predict PD-1 Inhibitor Treatment Efficacy in Intrahepatic Cholangiocarcinoma

Inflammation-based prognostic scores can be a valuable tool in assessing the overall survival of patients with intrahepatic cholangiocarcinoma. Read More.

2. FDA Grants Orphan Drug Designation to ZielBio’s ZB131 for Cholangiocarcinoma

The investigational drug is a monoclonal antibody with a high affinity and specificity for cancer-specific plectin, a cell surface protein that correlates with aggressive tumors and poor prognosis. Read More.

1. Derazantinib Shows Clinical Benefit, Manageable Safety Profile in Patients With Cholangiocarcinoma

Derazantinib is an investigational oral inhibitor of FGFR1, FGFR2, and FGFR3 in patients with locally advanced or metastatic intrahepatic cholangiocarcinoma. Read More.